Market News Comments

Pfizer (PFE)

Privately held Theraclone Sciences Inc., of Seattle, has signed a multiyear research and development collaboration with Pfizer Inc. for the company's in situ therapeutic antibody rescue (I-STAR) technology. The deal makes Theraclone eligible to receive up to $632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones, plus undisclosed royalties on future. Pfizer will be responsible for preclinical and clinical development of the antibodies.

Jan 20 · 4:55:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Post a Comment


Copyright © 2010
All rights reserved.